Publications by authors named "Steven D Podos"

Claim this Profile
F
First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases.
Venkat R Gadhachanda, Jason A Wiles, Steven D Podos, David Boyer, Jane Thanassi

Pharm Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases.
Venkat R Gadhachanda, Jason A Wiles, Steven D Podos, David Boyer, Jane Thanassi

Pharm Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Steven D Podos, Howard Trachtman, Gerald B Appel, Andrew S Bomback, Bradley P Dixon

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Carla Nester, Gerald B Appel, Andrew S Bomback, Koenraad Peter Bouman, H Terence Cook, Steven D Podos

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies.
David D Boyer, Ya-Ping Ko, Steven D Podos, Mark E Cartwright, Xiang Gao

Transl Vis Sci Technol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).
Jason A Wiles, Manuel D Galvan, Steven D Podos, Michael Geffner, Mingjun Huang

Curr Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Xuan Yuan, Eleni Gavriilaki, Jane A Thanassi, Guangwei Yang, Andrea C Baines, Steven D Podos

Haematologica· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic assessment of DNA ligase as an antibacterial target in Staphylococcus aureus.
Steven D Podos, Jane A Thanassi, Michael J Pucci

Antimicrob Agents Chemother· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.
Steven D Podos, Jane A Thanassi, Melissa Leggio, Michael J Pucci

Antimicrob Agents Chemother· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-step syntheses of nitrofuranyl benzimidazoles that are active against multidrug-resistant bacteria.
Garrett C Moraski, Jane A Thanassi, Steven D Podos, Michael J Pucci, Marvin J Miller

J Antibiot (Tokyo)· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.
Michael J Pucci, Steven D Podos, Jane A Thanassi, Melissa J Leggio, Barton J Bradbury

Antimicrob Agents Chemother· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Ha Young Kim, Jason A Wiles, Qiuping Wang, Godwin C G Pais, Edlaine Lucien, Steven D Podos

J Med Chem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibitors of E. coli primase, a novel bacterial target.
Atul Agarwal, Shirley Louise-May, Jane A Thanassi, Steven D Podos, Jijun Cheng

Bioorg Med Chem Lett· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Michael J Pucci, Jijun Cheng, Steven D Podos, Christy L Thoma, Jane A Thanassi

Antimicrob Agents Chemother· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Qiuping Wang, Edlaine Lucien, Akihiro Hashimoto, Godwin C G Pais, David M Nelson, Steven D Podos

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Jason A Wiles, Yongsheng Song, Qiuping Wang, Edlaine Lucien, Akihiro Hashimoto, Steven D Podos

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Jason A Wiles, Qiuping Wang, Edlaine Lucien, Akihiro Hashimoto, Yongsheng Song, Steven D Podos

Bioorg Med Chem Lett· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis